Kymera Therapeutics (KYMR) analyst forecast and price target
Analyst forecast
Consensus of 24 analyst ratings
Based on 11 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $170.00 from $135.00 | Aug 31, 2026 |
| Wells Fargo | Maintained | Overweight | $151.00 from $116.00 | Aug 27, 2026 |
| Barclays | Maintained | Overweight | $139.00 from $133.00 | Aug 6, 2026 |
| Deutsche Bank | Initiated Coverage | Hold | $120.00 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $135.00 from $125.00 | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $140.00 from $120.00 | Jul 16, 2026 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $115.00 from $106.00 | Jul 13, 2026 |
| B of A Securities | Maintained | Buy | $125.00 from $110.00 | Jun 30, 2026 |
| B. Riley Securities | Maintained | Buy | $155.00 from $117.00 | Jun 29, 2026 |
| Truist Securities | Maintained | Buy | $136.00 from $116.00 | Jun 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $129.00 from $106.00 | Jun 26, 2026 |
| BTIG | Maintained | Buy | $134.00 | Jun 25, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $106.00 | May 6, 2026 |
| Jefferies | Initiated Coverage | Buy | $110.00 from $122.00 | Mar 16, 2026 |
| UBS | Maintained | Buy | $128.00 from $90.00 | Mar 3, 2026 |
| Stephens & Co. | Maintained | Overweight | $100.00 from $95.00 | Mar 2, 2026 |
| Citigroup | Maintained | Buy | $120.00 from $110.00 | Mar 2, 2026 |
| Piper Sandler | Maintained | Overweight | $140.00 from $125.00 | Feb 26, 2026 |
| BTIG | Maintained | Buy | $134.00 from $138.00 | Feb 26, 2026 |
| BTIG | Maintained | Buy | $138.00 | Feb 3, 2026 |
Frequently asked questions
What is the price target for KYMR stock?
The average 12-month analyst price target for Kymera Therapeutics (KYMR) is $137.64, with a high estimate of $170.00 and a low of $115.00, across 11 analysts.
Is KYMR a buy, sell, or hold?
Analysts covering Kymera Therapeutics currently average a Buy rating: 21 buy, 3 hold and 0 sell, from 24 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for KYMR?
The average price target of $137.64 implies 16.90% upside from the last price of $117.74.
What is the latest analyst rating on KYMR?
On Aug 31, 2026, Guggenheim maintained Kymera Therapeutics at Buy with a price target of $170.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.